AI Engines For more Details: Perplexity Kagi Labs You
Antihistaminic Effects: Pheniramine maleate works by blocking the action of histamine, a substance in the body that causes allergy symptoms such as itching, sneezing, runny nose, and watery eyes. By inhibiting histamine activity, pheniramine helps alleviate these symptoms.
Relief of Allergic Symptoms: Pheniramine maleate is used to relieve symptoms of allergic rhinitis (hay fever), including nasal congestion, sneezing, itching, and runny nose. It can also help alleviate symptoms of allergic conjunctivitis, such as redness, itching, and tearing of the eyes.
Treatment of Itching: Pheniramine is effective in relieving itching associated with allergic reactions, insect bites, hives (urticaria), and other skin conditions. It can help reduce the urge to scratch, which can further irritate the skin and exacerbate symptoms.
Sedative Effects: Pheniramine has mild sedative properties, which can cause drowsiness or sleepiness in some individuals. This sedative effect may be beneficial for relieving symptoms of insomnia or promoting sleep in patients with allergies or colds. However, it can also impair alertness and coordination, so caution should be exercised when performing activities that require mental alertness, such as driving or operating machinery.
Relief of Cough: Pheniramine may have antitussive (cough-suppressant) effects, although it is not commonly used for this purpose. In combination products, pheniramine may help reduce cough associated with upper respiratory tract infections or allergic reactions.
Treatment of Cold Symptoms: Pheniramine maleate is included in some cold and flu medications to alleviate symptoms such as nasal congestion, runny nose, sneezing, and itchy throat. It is often combined with other active ingredients such as decongestants, analgesics (pain relievers), and antipyretics (fever reducers) for comprehensive relief of cold symptoms.
Side Effects: Common side effects of pheniramine maleate may include drowsiness, dry mouth, blurred vision, constipation, and urinary retention. These side effects are usually mild and temporary, but patients should be aware of them and report any persistent or bothersome symptoms to their healthcare provider.
Interactions: Pheniramine may interact with other medications, including central nervous system depressants (such as alcohol, sedatives, and tranquilizers), monoamine oxidase inhibitors (MAOIs), and other antihistamines. Patients should inform their healthcare provider about all medications they are taking to avoid potential drug interactions.
Precautions: Pheniramine should be used with caution in elderly patients, as they may be more susceptible to its sedative effects. It should also be used with caution in patients with narrow-angle glaucoma, urinary retention, asthma, or prostatic hypertrophy, as it may exacerbate these conditions.
Dosage: The dosage of pheniramine maleate may vary depending on the formulation and the patient's age, weight, and medical condition. It is essential to follow the dosage instructions provided by the healthcare provider or the product label carefully.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 2.9 | 0.6 | 3.83 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 2.3 | 1.5 | 0.53 |
| Allergies | 4.3 | 2.8 | 0.54 |
| Allergy to milk products | 1.8 | 1.2 | 0.5 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 4.7 | 5.2 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.7 | 0.9 | 3.11 |
| Ankylosing spondylitis | 3.8 | 1 | 2.8 |
| Anorexia Nervosa | 1 | 2.3 | -1.3 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 4.3 | 2.9 | 0.48 |
| Atherosclerosis | 1.3 | 1.9 | -0.46 |
| Atrial fibrillation | 2.9 | 1.4 | 1.07 |
| Autism | 7.5 | 6.5 | 0.15 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 1.5 | 1.7 | -0.13 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0 | 0 | |
| Cancer (General) | 0.6 | 1.1 | -0.83 |
| Carcinoma | 3.3 | 2.2 | 0.5 |
| Celiac Disease | 1.6 | 3.2 | -1 |
| Cerebral Palsy | 1.6 | 1.3 | 0.23 |
| Chronic Fatigue Syndrome | 3.8 | 4 | -0.05 |
| Chronic Kidney Disease | 3.7 | 2.5 | 0.48 |
| Chronic Lyme | 0.3 | 0.8 | -1.67 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 1.7 | -0.55 |
| Chronic Urticaria (Hives) | 1.2 | 0.9 | 0.33 |
| Coagulation / Micro clot triggering bacteria | 0.9 | 1.3 | -0.44 |
| Cognitive Function | 2.6 | 1.4 | 0.86 |
| Colorectal Cancer | 4.5 | 1.5 | 2 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.6 | 2 | -0.25 |
| COVID-19 | 6.8 | 8.9 | -0.31 |
| Crohn's Disease | 5.4 | 5 | 0.08 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.6 | 1.4 | -1.33 |
| d-lactic acidosis (one form of brain fog) | 0 | 0 | |
| deep vein thrombosis | 1.5 | 1.4 | 0.07 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 7.3 | 7.7 | -0.05 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.3 | 1.1 | 0.18 |
| Endometriosis | 2.5 | 2 | 0.25 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.5 | 1.8 | 0.39 |
| erectile dysfunction | 0.9 | 0.3 | 2 |
| Fibromyalgia | 2.1 | 1.4 | 0.5 |
| Functional constipation / chronic idiopathic constipation | 3.9 | 3.1 | 0.26 |
| gallstone disease (gsd) | 2.2 | 1.3 | 0.69 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 1.2 | -2 |
| Generalized anxiety disorder | 2.5 | 1.9 | 0.32 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.6 | 0.8 | 1 |
| Graves' disease | 1.5 | 3.3 | -1.2 |
| Gulf War Syndrome | 0.7 | 1.7 | -1.43 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.7 | 2 | 0.85 |
| Heart Failure | 2.7 | 1.7 | 0.59 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.6 | 0.6 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.6 | -1 |
| hyperglycemia | 2.1 | 1.8 | 0.17 |
| Hyperlipidemia (High Blood Fats) | 1.1 | 0.3 | 2.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.8 | 4.5 | 0.07 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 2.3 | 0.3 | 6.67 |
| IgA nephropathy (IgAN) | 1.2 | 3.4 | -1.83 |
| Inflammatory Bowel Disease | 5.4 | 6.8 | -0.26 |
| Insomnia | 2.1 | 3.2 | -0.52 |
| Intelligence | 0.8 | 0.2 | 3 |
| Intracranial aneurysms | 0.7 | 0.6 | 0.17 |
| Irritable Bowel Syndrome | 6.9 | 4.7 | 0.47 |
| ischemic stroke | 1.9 | 1.4 | 0.36 |
| Liver Cirrhosis | 6 | 4.6 | 0.3 |
| Long COVID | 4.7 | 6.5 | -0.38 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1.6 | -0.78 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 0.3 | 1.6 | -4.33 |
| ME/CFS without IBS | 1.3 | 1.2 | 0.08 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.3 | 1 | 0.3 |
| Metabolic Syndrome | 5.7 | 5.8 | -0.02 |
| Mood Disorders | 7.8 | 6.2 | 0.26 |
| multiple chemical sensitivity [MCS] | 1.3 | 0.1 | 12 |
| Multiple Sclerosis | 5.2 | 3 | 0.73 |
| Multiple system atrophy (MSA) | 1.4 | 0.7 | 1 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 0.3 | 3 | -9 |
| Neuropathy (all types) | 1.2 | 1.8 | -0.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.7 | 4.5 | 0.04 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 9 | 6.7 | 0.34 |
| obsessive-compulsive disorder | 4.1 | 3.7 | 0.11 |
| Osteoarthritis | 1.8 | 1.6 | 0.13 |
| Osteoporosis | 2.3 | 1.9 | 0.21 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7.8 | 4.8 | 0.63 |
| Polycystic ovary syndrome | 4 | 3.1 | 0.29 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 0.8 | 0.5 |
| Primary sclerosing cholangitis | 1.5 | 1.4 | 0.07 |
| Psoriasis | 2.5 | 1.9 | 0.32 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.3 | 3.1 | 1.03 |
| Rosacea | 1.2 | 0.5 | 1.4 |
| Schizophrenia | 4.9 | 2.9 | 0.69 |
| scoliosis | 0.3 | 0.8 | -1.67 |
| Sjögren syndrome | 2.4 | 1.6 | 0.5 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.3 | 3 |
| Stress / posttraumatic stress disorder | 2.2 | 2.9 | -0.32 |
| Systemic Lupus Erythematosus | 2.7 | 1.9 | 0.42 |
| Tic Disorder | 0.9 | 1.4 | -0.56 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 3.5 | 2.8 | 0.25 |
| Type 2 Diabetes | 5.7 | 5.1 | 0.12 |
| Ulcerative colitis | 3.2 | 5 | -0.56 |
| Unhealthy Ageing | 3.2 | 1.9 | 0.68 |
| Vitiligo | 1.6 | 1.2 | 0.33 |
